386 related articles for article (PubMed ID: 22069614)
1. The double-edged sword of autoimmunity: lessons from multiple sclerosis.
Hestvik AL
Toxins (Basel); 2010 Apr; 2(4):856-77. PubMed ID: 22069614
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.
Van Kaer L
Exp Neurol; 2011 Jan; 227(1):19-23. PubMed ID: 20969865
[TBL] [Abstract][Full Text] [Related]
4. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.
Ben-Nun A; Mendel I; Bakimer R; Fridkis-Hareli M; Teitelbaum D; Arnon R; Sela M; Kerlero de Rosbo N
J Neurol; 1996 Apr; 243(4 Suppl 1):S14-22. PubMed ID: 8965116
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.
Arnon R; Aharoni R
J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.
Stüve O; Youssef S; Weber MS; Nessler S; von Büdingen HC; Hemmer B; Prod'homme T; Sobel RA; Steinman L; Zamvil SS
J Clin Invest; 2006 Apr; 116(4):1037-44. PubMed ID: 16543951
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
Aharoni R
J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
[TBL] [Abstract][Full Text] [Related]
8. Insights into the immunopathogenesis of multiple sclerosis.
Hellings N; Raus J; Stinissen P
Immunol Res; 2002; 25(1):27-51. PubMed ID: 11868933
[TBL] [Abstract][Full Text] [Related]
9. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.
Yong VW
Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
Mahurkar S; Suppiah V; O'Doherty C
Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
Aharoni R
Autoimmun Rev; 2013 Mar; 12(5):543-53. PubMed ID: 23051633
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
[TBL] [Abstract][Full Text] [Related]
14. Recent insights into the mechanism of action of glatiramer acetate.
Kala M; Miravalle A; Vollmer T
J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
Liblau R
J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
Dhib-Jalbut S
Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
[TBL] [Abstract][Full Text] [Related]
17. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
Ragheb S; Abramczyk S; Lisak D; Lisak R
Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
Dhib-Jalbut S
Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.
Hohlfeld R; Wekerle H
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14599-606. PubMed ID: 15306684
[TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.
Burger D; Molnarfi N; Weber MS; Brandt KJ; Benkhoucha M; Gruaz L; Chofflon M; Zamvil SS; Lalive PH
Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4355-9. PubMed ID: 19255448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
